Erratum: Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination

Raeven, René H. M.; Brummelman, Jolanda; Pennings, Jeroen L. A.; Maas, Larissa van der; Helm, Kina; Tilstra, Wichard; Ark, Arno van der; Sloots, Arjen; Ley, Peter van der; Eden, W. (Willem) van; Jiskoot, Wim; Riet, Elly van; Els, C.A.C.M. van; Kersten, Gideon; Han, Wei-Dong; Metz, Bernard

doi:10.1038/mi.2017.110

Cited by 14 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or i.n. a Mice Decreased bacterial colonization in the lungs [34] OMVs OMV components — s.c. Mice Decrease bacterial colonization in the lungs; slightly faster than that of wPV OMVs OMV components — PM a or s.c. Mice Decreased bacterial colonization in the lungs, trachea, and nose [35] OMVs deriving from B. parapertussis OMV components — i.p. Mice Cross-protection [36] Lipid A-modified OMVs OMV components — i.n.…”

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

“…Among them, OMVs have been most thoroughly studied. Many studies have demonstrated that OMVs derived from B. pertussis can protect mice from intranasal pertussis challenge through different immune routes, including intraperitoneal, subcutaneous, intranasal, and pulmonary (PM) [34] , [35] , [76] . The classical administration route of OMVs is subcutaneous or intraperitoneal, which does not cause an IgA reaction [77] .…”

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Prophylactic vaccines have evolved from traditional whole-cell vaccines to safer subunit vaccines. However, subunit vaccines still face problems, such as poor immunogenicity and low efficiency, while traditional adjuvants are usually unable to meet specific response needs. Advanced delivery vectors are important to overcome these barriers; they have favorable safety and effectiveness, tunable properties, precise location, and immunomodulatory capabilities. Nevertheless, there has been no systematic summary of the delivery systems to cover a wide range of infectious pathogens. We herein summarized and compared the delivery systems for major or epidemic infectious diseases caused by bacteria, viruses, fungi, and parasites. We also included the newly licensed vaccines (e.g., COVID-19 vaccines) and those close to licensure. Furthermore, we highlighted advanced delivery systems with high efficiency, cross-protection, or long-term protection against epidemic pathogens, and we put forward prospects and thoughts on the development of future prophylactic vaccines.

show abstract

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Pulmonary vaccination with OMV using a microspray aerosolizer has also been evaluated and was found to lead to improved protection over subcutaneous immunization ( 41 ). It induced mucosal IgA and Th17-type responses, as well as systemic IgG, memory B cells and Th17 cells, while only systemic responses were induced by subcutaneous administration of the OMV.…”

Section: Resultsmentioning

confidence: 99%

Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives

Dubois

Locht

2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCurrent vaccination strategies against pertussis are sub-optimal. Optimal protection against Bordetella pertussis, the causative agent of pertussis, likely requires mucosal immunity. Current pertussis vaccines consist of inactivated whole B. pertussis cells or purified antigens thereof, combined with diphtheria and tetanus toxoids. Although they are highly protective against severe pertussis disease, they fail to elicit mucosal immunity. Compared to natural infection, immune responses following immunization are short-lived and fail to prevent bacterial colonization of the upper respiratory tract. To overcome these shortcomings, efforts have been made for decades, and continue to be made, toward the development of mucosal vaccines against pertussis.ObjectivesIn this review we systematically analyzed published literature on protection conferred by mucosal immunization against pertussis. Immune responses mounted by these vaccines are summarized.MethodThe PubMed Library database was searched for published studies on mucosal pertussis vaccines. Eligibility criteria included mucosal administration and the evaluation of at least one outcome related to efficacy, immunogenicity and safety.ResultsWhile over 349 publications were identified by the search, only 63 studies met the eligibility criteria. All eligible studies are included here. Initial attempts of mucosal whole-cell vaccine administration in humans provided promising results, but were not followed up. More recently, diverse vaccination strategies have been tested, including non-replicating and replicating vaccine candidates given by three different mucosal routes: orally, nasally or rectally. Several adjuvants and particulate formulations were tested to enhance the efficacy of non-replicating vaccines administered mucosally. Most novel vaccine candidates were only tested in animal models, mainly mice. Only one novel mucosal vaccine candidate was tested in baboons and in human trials.ConclusionThree vaccination strategies drew our attention, as they provided protective and durable immunity in the respiratory tract, including the upper respiratory tract: acellular vaccines adjuvanted with lipopeptide LP1569 and c-di-GMP, outer membrane vesicles and the live attenuated BPZE1 vaccine. Among all experimental vaccines, BPZE1 is the only one that has advanced into clinical development.

show abstract

“…route for the generation of B. pertussis -specific T RM cells (Allen et al, 2018). Furthermore, studies with B. pertussis OMV have demonstrated that pulmonary immunization is more effective than the s.c. route of immunization for induction of CD103 + T RM cells (Raeven et al, 2018). Therefore, a “prime and pull” strategy of systemic priming followed by nasal boosting might be an interesting approach for induction of systemic and local memory immune response against B. pertussis (Shin and Iwasaki, 2012).…”

Section: Discussionmentioning

confidence: 99%

A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains

Zurita

Wilk

Carriquiriborde

et al. 2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Pertussis is a respiratory infectious disease that has been resurged during the last decades. The change from the traditional multi-antigen whole-cell pertussis (wP) vaccines to acellular pertussis (aP) vaccines that consist of a few antigens formulated with alum, appears to be a key factor in the resurgence of pertussis in many countries. Though current aP vaccines have helped to reduce the morbidity and mortality associated with pertussis, they do not provide durable immunity or adequate protection against the disease caused by the current circulating strains of Bordetella pertussis , which have evolved in the face of the selection pressure induced by the vaccines. Based on the hypothesis that a new vaccine containing multiple antigens could overcome deficiencies in the current aP vaccines, we have designed and characterized a vaccine candidate based on outer membrane vesicle (OMVs). Here we show that the OMVs vaccine, but not an aP vaccine, protected mice against lung infection with a circulating pertactin (PRN)-deficient isolate. Using isogenic bacteria that in principle only differ in PRN expression, we found that deficiency in PRN appears to be largely responsible for the failure of the aP vaccine to protect against this circulating clinical isolates. Regarding the durability of induced immunity, we have already reported that the OMV vaccine is able to induce long-lasting immune responses that effectively prevent infection with B. pertussis . Consistent with this, here we found that CD4 T cells with a tissue-resident memory (T RM ) cell phenotype (CD44 + CD62L low CD69 + and/or CD103 + ) accumulated in the lungs of mice 14 days after immunization with 2 doses of the OMVs vaccine. CD4 T RM cells, which have previously been shown to play a critical role sustained protective immunity against B. pertussis , were also detected in mice immunized with wP vaccine, but not in the animals immunized with a commercial aP vaccine. The CD4 T RM cells secreted IFN-γ and IL-17 and were significantly expanded through local proliferation following respiratory challenge of mice with B. pertussis . Our findings that the OMVs vaccine induce respiratory CD4 T RM cells may explain the ability of this vaccine to induce long-term protection and is therefore an ideal candidate for a third generation vaccine against B. pertussis .

show abstract

Erratum: Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination

Cited by 14 publications

References 0 publications

Prophylactic vaccine delivery systems against epidemic infectious diseases

Prophylactic vaccine delivery systems against epidemic infectious diseases

Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives

A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains

Contact Info

Product

Resources

About